$7.96
Insights on Zivo Bioscience Inc
In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 124.4%
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 304.2%
60.68%
Downside
Day's Volatility :60.73%
Upside
0.13%
93.97%
Downside
52 Weeks Volatility :96.31%
Upside
38.77%
Period | Zivo Bioscience Inc | Index (Russel 2000) |
---|---|---|
3 Months | -11.56% | 0.0% |
6 Months | 1229.44% | 0.0% |
1 Year | -52.7% | 0.0% |
3 Years | -69.08% | -22.6% |
Market Capitalization | 22.5M |
Book Value | - $0.93 |
Earnings Per Share (EPS) | -3.81 |
PEG Ratio | 0.0 |
Wall Street Target Price | 12.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -16072.75% |
Return On Assets TTM | -338.92% |
Return On Equity TTM | -3956.02% |
Revenue TTM | 27.7K |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 20.0K |
Diluted Eps TTM | -3.81 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.76 |
EPS Estimate Next Year | -2.2 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 50.75%
Sell
Neutral
Buy
Zivo Bioscience Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Zivo Bioscience Inc | 6.13% | 1229.44% | -52.7% | -69.08% | -68.34% |
Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Zivo Bioscience Inc | NA | NA | 0.0 | -2.76 | -39.56 | -3.39 | NA | -0.93 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Zivo Bioscience Inc | Buy | $22.5M | -68.34% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
BARTLETT & Co WEALTH MANAGEMENT LLC
zivo bioscience, inc., a u.s.-based r&d firm, is dedicated to the study, development and commercialization of natural nutritional compounds and bioactive molecules derived from proprietary algal strains.
Organization | Zivo Bioscience Inc |
Employees | 8 |
CEO | Mr. John B. Payne |
Industry | Consumer Non-Durables |
A Spac I Acquisition Corp
$7.96
+0.0%
Keyarch Acquisition Corp
$7.96
+0.0%
Connexa Sports Technologies Inc
$7.96
+0.0%
Us Value Etf
$7.96
+0.0%
First Wave Biopharma Inc
$7.96
+0.0%
Global X Msci Next Emerging
$7.96
+0.0%
Fat Projects Acquisition Corp
$7.96
+0.0%
Goal Acquisitions Corp
$7.96
+0.0%
Capital Link Global Fintech
$7.96
+0.0%